Kymera Investor Presentation Deck

KYMERA Recognized leader in Targeted Protein Degradation (TPD) Building a fully-integrated, global biotech company Initial I/I and Oncology focus, but a disease-agnostic platform Accelerating forward integration through key strategic partnerships KYMERA Ⓒ2023 KYMERA THERAPEUTICS, INC. ● ● ● ● ● ● Overview Key Accomplishments Advanced four programs to clinical stage Developed a deep pipeline positioned to deliver ≥1 IND/year First to advance degrader (KT-474/SAR444656) in healthy volunteers and patients with HS and AD Demonstrated degrader vs. small molecule inhibitors (SMI) biological and clinical differentiation, and potential best in class profile in I/I Demonstrated fidelity of translation of PK, PD and safety across three clinical programs in I/I and oncology patients Unique target selection strategy based on using TPD to unlock high value, undrugged targets Well-capitalized with $516m of cash, enabling expansion of clinical impact into areas with large clinical and commercial opportunities PAGE 3

View entire presentation